En vivo

FierceBiotechIn next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach CellDecoding the spatiotemporal development of human meninges CellFronto-insular circuit mechanisms of accelerated intermittent theta burst stimulation CellPhysiological brain clearance architecture revealed by neuronal protein tracing FierceBiotechASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’Endpoints NewsCan AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more IlluminaIllumina Ducks DNA Sequence Rival's Antitrust Suit, For Now - Law360 BioPharma DiveAt ASCO, Merck makes case for a ‘cornerstone’ cancer drug BioPharma DiveBristol Myers unveils data for one of its next-gen blood cancer drugs Clinical OMICsTeclistamab Outperforms Standard Therapy in Relapsed Multiple Myeloma Clinical OMICsAI Chatbots Do Not Consistently Deliver Accurate Health Responses FierceBiotechLegend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform

Clinical OMICs 29 may 2026

Teclistamab Outperforms Standard Therapy in Relapsed Multiple Myeloma

Results from the Phase III MajesTEC-9 trial show that teclistamab delivers deeper and more durable responses than standard treatments in patients with relapsed...

Results from the Phase III MajesTEC-9 trial show that teclistamab delivers deeper and more durable responses than standard treatments in patients with relapsed multiple myeloma, supporting earlier use of bispecific immunotherapy. The post Teclistamab Outperforms Standard Therapy in Relapsed Multiple Myeloma appeared first on Inside Precision Medicine .